Related by context. All words. (Click for frequent words.) 69 FARESTON ® 69 Naglazyme galsulfase 64 Aprovel R 63 Aldurazyme laronidase 62 Vancocin R 61 LIDODERM 61 DOVONEX 61 COLAZAL R 60 ZANAFLEX CAPSULES 60 Azactam 60 LUCENTIS r 60 Ethyol 59 Programmer Paradise segment 59 Nascobal ® 59 Zovirax ® 59 PENTASA 59 netsales 58 ARCALYST ® 58 #compared 58 totaled USD#.#m 58 Roche OTC RHHBY 58 Adjusted EBITDA1 58 3Q FY# 58 1Q FY# 58 months endedSeptember 58 Zanaflex 58 ZEFFIX 58 Treximet ® 57 MXN#.# billion [001] 57 Frova R 57 Xibrom TM 57 Phosphates segment 57 CARBATROL 57 Fanapt iloperidone 57 Somatuline Depot 57 THALOMID R 57 totaled EUR#.# 57 ZETIA totaled 57 Yidasheng totaled RMB#.# 56 Agenerase 56 DELATESTRYL 56 THALOMID 56 ARCALYST R 56 LIALDA MEZAVANT 56 Lilly ICOS LLC 56 SEK#.#m [001] 56 BioMarin Genzyme LLC 56 Aloxi injection 56 RAPTIVA r 56 FROVA 56 Ixempra 56 XOPENEX Inhalation Solution 56 Soriatane R 56 CLP#.# trillion 56 Luveris R Ovidrel R 56 Infergen R 56 unconsolidated joint 56 Sensipar R 56 Medco Accredo specialty 56 Eloxatin ® 56 VANTAS R 56 millioncompared 56 OPANA franchise 56 Individual Annuities segment 56 ABILIFY ® 56 MOVIPREP R 56 Zanaflex tablets 56 R sorafenib tablets 56 Wellbutrin XL R 55 adjusted1 55 JPY8 55 Oxy ER 55 BioSante Pharmaceuticals Announces 55 Amaryl R 55 ABILIFY R 55 Licorice Products segment 55 - Revenues [013] 55 SunOpta Foods 55 Biaxin clarithromycin 55 Independent Leg Jackup 55 Sensipar ® 55 #Q# #Q# [003] 55 Neulasta R 55 fludarabine phosphate 55 Istalol 55 Celgene Thalomid 55 USD#.#m [008] 55 Benicar HCT 55 ASUR regulated 55 Scantron segment decreased 55 was#.# 55 DILUTED SHARE 55 Ultane Sevorane 54 kroner euro#.# [002] 54 AVONEX ® 54 ascompared 54 totaled MEUR 54 Unitrin Specialty segment 54 JPY6 54 Xeloda ® 54 R exenatide injection 54 NET CASH FLOW FROM 54 Dorzolamide 54 comparedwith 54 Trelstar R 54 totaled EUR#.#m 54 Fanapt ® 54 BLU U R 54 Timolol ophthalmic solution 54 PHP#.# bln 54 OLEPTRO ™ 54 NET REVENUES 54 comparedto 54 EBITD 54 -IPLT#.com 54 increaseof 54 operatingincome 54 Recurring royalties 54 3Q FY# representing 54 PRAVACHOL R 54 XYREM 54 Actimmune R 54 BioGlue R 54 Sanctura 54 RAPTIVA 54 prioryear 54 SUPPRELIN R LA 54 LUCENTIS 54 ZALBIN ™ 53 crore QoQ 53 BD Biosciences segment 53 Milestone Payments 53 Rx Pharmaceuticals 53 interferon gamma 1b 53 USD#.#m [007] 53 #.#/diluted share 53 totaled Ps 53 Taxotere docetaxel 53 RMB2 #.# 53 VANTAS 53 ABELCET 53 Gross Margin Gross 53 Vitaflo Scandinavia AB 53 - Non GAAP [031] 53 RUB#.# billion [001] 53 - Revenues [009] 53 Angiomax Angiox 53 ACTONEL 53 nonsedating antihistamine 53 Peginterferon alfa 2b 53 Second Quarter Highlights 53 ended September# 53 Benicar ® 53 Highlights - 53 ııı#.# billion [002] 53 2Q FY# representing 53 Teveten 53 ZANAFLEX tablets 53 Azmacort R 53 - - [030] 53 - Revenues [005] 53 Wholesale Leathercraft 53 IDR#.# billion [002] 53 -# -# -#,# 53 Maxipime 53 Inc HNT 53 Nipent R 53 Scantron segment increased 53 HealthStream Learning 53 USD #.#bln [001] 53 SUPPLEMENTAL INFORMATION RECONCILIATION OF 53 Milestone Payment 53 include WebSphere DB2 53 R hylan GF 53 Somatuline R Depot 53 PLAVIX R 53 #,# -#,# #,# 53 Non CWI 52 please visit http:/www.vandapharma.com 52 Gabitril 52 CHF#.# billion [002] 52 ® bortezomib 52 NASDAQ MOGN 52 monthsended 52 RESTASIS 52 Q3 FY'# 52 - - [057] 52 4Q FY# 52 #.#Â [001] 52 dextromethorphan quinidine 52 FOR FURTHER INFORMATION ABOUT 52 INSPIRE Trial Phase III 52 Expense Expense 52 Decline Quick Facts 52 LUMIGAN R 52 EU#.# billion [002] 52 CNH GLOBAL NV 52 - OperatiMcGrath RentCorp 52 Nascobal R 52 -Subscribes 52 More Than Quadruples 52 ONTAK 52 MBS AFS increased 52 Profit Declines Quick Facts 52 9M FY# [001] 52 Thalomid ® 52 Broadspire segment 52 #.#B +#.# 52 DepoDur R 52 SUPPRELIN LA 52 TO NET LOSS 52 XAGRID 52 Gross Profit Gross 52 Explosive Metalworking segment 52 RMB#.#million 52 ev3 peripheral vascular 52 = Income [001] 52 IV Busulfex 51 adjusted2 51 #,#,# #,#,# GROSS PROFIT [002] 51 Components Segment 51 Kerastick 51 Currency translation negatively impacted 51 Tritace R 51 AZASITE 51 Revenue Grows 51 AVINZA ® 51 Sees FY 51 Novogyne 51 SALES SLUMP 51 STRIANT 51 Mircette R 51 ninemonths 51 totaled E#.# 51 Argatroban 51 Motorhome Resorts Segment 51 flattish sequentially 51 Polyurethanes segment 51 collaborator Bayer HealthCare 51 Income Rises 51 Pretax Income 51 Kyowa Kirin 51 ALMOST FAMILY INC. AND 51 RMB4 #.# 51 Zevalin R Ibritumomab 51 RMB3 #.# 51 Developer Journal dotnetaddict.dotnetdevelopersjouZhengming 51 subsidiary MHN provides 51 # -Ludivine Kreutz 51 Including discontinued operations 51 loss NOL carryforward 51 Lilly ICOS joint venture 51 OTHER EXPENSE 51 millionfor 51 profit beia 51 PLAVIX ® 51 RUR#.#bn approx. [001] 51 TO TOTAL LOANS 51 Peripheral vascular 51 continuingoperations 51 Fumapharm AG 51 PLN #.#mn [004] 51 - Operating [014] 51 sameperiod 50 - Adjusted [006] 50 Interest Income Expense 50 EUR -#.# -#.# [001] 50 Competitive Wireline 50 #-#/# #-#/# Change [001] 50 MNOK #.# 50 to#.# [003] 50 SinuNase ™ 50 RAPTIVA R 50 -DD2 50 Proquin XR 50 operating income1 50 Targretin capsules 50 Favourable Changes total 50 Ended #/#/# #/#/# [002] 50 EBT amounted 50 - - [006] 50 - TOTALeading Tickles 50 - Operating [028] 50 EBIT amounted 50 Inc. NASDAQ EVVV 50 - - Total [058] 50 - Rdetrimentally affected 50 Trailing Twelve Months 50 Ps.2 50 MXN#.# [004] 50 Cetrotide R 50 SPRYCEL ® 50 Janssen AI 50 1Q FY# representing 50 YonY 50 Ps.5 50 palonosetron hydrochloride injection 50 EUR#.#B [005] 50 Ps.3 50 Lilly ICOS 50 Taiho Pharmaceutical 50 R pegaptanib sodium 50 EUR#.#million 50 Olefins Polyolefins 50 CHF #.#M 50 CAD#.# [002] 50 NOK#.# billion [002] 50 AND CASH FLOW 50 totaled SEK 50 ¥ #.#bn [004] 50 adjusted OIBDA decreased 50 - Non GAAP [008] 50 € #,# bn [002] 50 Q1 FY'# 50 income1 50 FHLB borrowings decreased 50 LifeVantage Announces 50 - Operating [016] 50 nine monthsended 50 JPY#.# billion [002] 50 - TOTAL [012] 50 Non GAAP Operating Margin 50 CLP#.# billion [001] 50 - Adjusted [030] 50 TPIAO 50 - Operating [030] 50 excluding BIBP 50 Non GAAP Gross Margin 50 Clinical Diagnostics segment 50 - Operating [026] 50 Cold Remedy segment 50 Receive Milestone Payment 50 Pro Forma Adjusted 50 c Includes 50 Pro forma EBITDA 50 Reimbursable costs 50 Unitrin Direct segment 50 EBITDAO 50 - -Anna Morena Baccarin 49 Million Milestone Payment 49 IV APAP 49 - Adjusted [012] 49 BEFORE TAXES 49 Mortgage loan originations 49 Expense Income 49 - Babelgum Online 49 - OCBSO 49 markets Testim ® 49 ZALBIN 49 Proforma Proforma 49 - Stave Lake 49 Rise Update3 49 Q2 FY# [001] 49 ofapproximately 49 RUR#.# [002] 49 RM#.#mil [002] 49 Noven Therapeutics 49 cinacalcet HCl 49 USD#.#m [001] 49 Rs#.#mn [001] 49 Vinyls segment 49 DBM Segment 49 CVS drugstores rose 49 Consolidated -Bektaşi 49 UNITS SOLD 49 RMB#.# [006] 49 - Operating [025] 49 totaled RUB 49 Q#'# Q#'# 49 Retail Leathercraft 49 Profit Rises Quick Facts 49 = Adjusted [005] 49 AVINZA 49 Jostens Scholastic 49 adjusted1 net 49 Cardiac Surgery Systems 49 More Than Doubled 49 excluding exceptionals 49 #,#.# #,#.# - [002] 49 PLN #.#m [001] 49 cents ashare 49 Unaudited Unaudited -PSE.com 49 Adjusted EBT 49 Q2 FY'# 49 NET PROFIT UP 49 Rs #.# lacs [001] 49 Mln Vs 49 Cytogen marketed 49 Adjusted Gross Profit 49 -Brad Dorfman editing 49 NEUPOGEN R 49 dacetuzumab collaboration 49 Normalized EPS 49 Revenues Grew 49 theprior 49 - Operating [004] 49 thequarter ended 49 - Operating [029] 49 #.#.# RON 49 - REVENUES [006] 49 and#.# [002] 49 EBITA amounted 49 - Revenues [006] 49 Wireline adjusted EBITDA 49 totaled BRL#.# 49 Normalized EBITDA 49 CRINONE R 49 - Unaudited UnauditWatercutter 49 copromotion 49 - - Non GAAP [007] 49 DAC offsets 49 Auxilium Pharma 49 Angelini Labopharm 49 USOGP 49 - OperAyscough 49 Continuing Ops 49 Q#-#/# 49 INTEGRILIN ® 49 -BiH Presidency 49 -Nongsa Point Marina 49 per dilutedshare 49 n#.# [002] 49 SEK1 #m 49 DISCONTINUED OPERATIONS Loss 49 HERCULES OFFSHORE INC. AND 49 endedSeptember 49 Widens Quick Facts 49 NOI decreased 49 JPY9 49 -Gunnlaugsson 49 CHF#.#B 49 Rmb#.# [006] 49 Ps.1 #.# 48 TOTAL OPERATING INCOME 48 BioGlue ® 48 CIMZIA ® 48 Receives Milestone Payment 48 date Wholesale Leathercraft 48 Klean Prep TM 48 NEC Nemertes NeoPath Neoware 48 Pro Forma Revenues 48 AMORTIZATION 48 - - [061] 48 Q1 #F 48 -Coco Reef 48 - Non GAAP [002] 48 Bertek Pharmaceuticals 48 MYR#.# [005] 48 Angio Seal TM 48 SORL consolidated 48 - Adjusted [016] 48 Before Unusual Items 48 - - [103] 48 Nexavar prescribing 48 CHANGES IN SHAREHOLDERS EQUITY 48 fiscal# 48 FINANCIAL ACCOUNT 48 Residential Furnishings 48 Benicar R 48 Premiums Written 48 Rs.#.# Crores [001] 48 - Operating [007] 48 Gypsum Wallboard 48 - Operatinluddites 48 #,#.#,#.# 48 Adjusted Operating Expenses 48 gallium arsenide GaAs substrate 48 Esprit Pharma 48 excluding reimbursable 48 QSI SG & 48 - Non GAAP [028] 48 - Operating [009] 48 #.#bn rub [003] 48 JPY4 48 Tiuxetan 48 EBITDA excl 48 #.#per diluted 48 - Non Shane Germann 48 Rs.#.# Cr [003] 48 Hugoton Properties 48 Paperboard Packaging segment 48 Inc. NASDAQ ZLCS 48 NET CASH 48 #-#/# #-#/# [006] 48 -BioCryst Pharmaceuticals NASDAQ BCRX 48 evaluating satraplatin 48 Q#/FY# 48 SEK -#.# [003] 48 AED#.#m 48 = Adjusted [002] 48 Interest Expenses 48 Headline PBIT 48 JPY#.#bn [003] 48 REVENUES Product 48 novel orally inhaled 48 THIRD QUARTER HIGHLIGHTS 48 AND DEVELOPMENT EXPENSES 48 MEUR -#.# 48 Generics Segment 48 NYSE HNT 48 EU#.# [004] 48 Xcytrin R 48 Eligard ® 48 #.#/Share [002] 48 -#,# -#,# [005] 48 Fresenius Kabi achieved 48 EUR1 #.#m 48 Rmb #.# 48 USD#.#bn [002] 48 Restated Restated Net 48 loan originations totaled 48 # # # [001] 48 Polymer Additives segment 48 RUR#.#bn approx. USD#m [003] 48 #.# BBtu d 47 Akorn Strides LLC 47 NOK#.# [005] 47 R epinastine HCl 47 Fully diluted EPS 47 #.Net 47 Colonial PCA 47 - Operating [022] 47 nonoperating expense 47 #,#,# = [017] 47 = Loss [007] 47 Operating Expense Ratio 47 thousand BOEPD 47 MNOK #,# 47 Third Consecutive Quarter 47 Nonperforming Assets Nonaccrual loans 47 Favourable Changes 47 FHLB advances decreased 47 Exceptional Items 47 CHF#.# [001] 47 Lexiscan R 47 = Net [019] 47 Beats Views 47 reaped RMB 47 - -Steven Heydemann Middle East 47 PentaStaph 47 dutogliptin 47 Eligard R 47 Immunotherapeutic 47 highly purified pasteurized 47 #,# #,# #,# #,# [005] 47 NONINTEREST EXPENSE 47 please visit www.middlebrookpharma.com 47 loan chargeoffs 47 RUR#.#bn [006] 47 Gemzar ® 47 Celera Diagnostics joint venture 47 BEUR 47 Unfavourable Changes 47 Operating Expenses Operating 47 - Non GAAP [011] 47 ELESTAT 47 EBITDA1 47 millionand 47 Pro forma adjusted EBITDA 47 GBP #.#m [003] 47 % unannualized 47 - - [029] 47 pentadentate logo R 47 - Operating [019] 47 Kosan dependence 47 CENTRAL PACIFIC FINANCIAL CORP. 47 % WEIGHTED AVG 47 - - [036] 47 n#.# [001] 47 Euro#.# [003] 47 -#,# -#,# [010] 47 #-#/# #-#/# #-#/# [003] 47 Pro forma EPS 47 SECOND QUARTER HIGHLIGHTS 47 deducting underwriting 47 Asentar TM 47 - Operating [008] 47 Month Period 47 SECOND QUARTER RESULTS 47 Evoltra ® 47 OshKosh wholesale 47 Captisol ® 47 Rs.# crores Rs.# crores 47 SIX BSLN announces 47 Dow Jones SHORT SELLING 47 Almost Triples 47 OPERATIONS TO ADJUSTED 47 Wtd 47 AUD#.# [004] 47 Long Term TIC Flows 47 BEST BALL 47 audited unaudited unaudited 47 PLN #.#mn [001] 47 -AL Gustin 47 CNY#.# Billion 47 Ps.4 47 #,#.# [014] 47 Prepaid churn 47 YTD Fiscal 47 WEIGHTED AVG 47 SEK#.#bn [004] 47 EU#.# [003] 47 Resilient Flooring 47 Pt Chg 47 Rs #.# lacs [002] 47 Haverty Furniture Reports 47 EUR#.#M [003] 47 CECT branded handsets 47 BY USED IN 47 excludes unrealized gains 47 BETTER BALL 47 Polyphenon ® E 47 EBITDAA 47 INCOME FROM CONTINUING OPERATIONS 47 Pruvel 47 - Non GAAP [019] 47 OTHER NON 47 FINANCIAL DETAILS 47 CONTROLLING INTEREST 47 Gross Profit Percentage 47 Qtr Qtr 47 nyse HNT 47 novel emulsion formulation 47 INTEGRILIN R eptifibatide Injection 47 GAAP Diluted EPS 47 RUB #.# [002] 47 - Operating [010] 47 EUR Mio 47 Revenue Climbs 47 TRY#.# [005] 47 Pruvel TM 47 = NetSao Pedro 47 TWD#.# [005] 47 expenses totaled Ps 47 GCUK generated 47 = Reconciliation [016] 47 #-#/# #-#/# #-#/# [004] 47 - - [016] 47 Elestat 47 ` #cr [002] 47 - Revenues [001] 47 apaziquone 47 - Operating [003] 47 IDR#.# trillion [002] 47 Targeted Chemotherapy 47 noninterest expense decreased 47 Current Portion 47 offiscal 47 Overall NewMarket 47 paclitaxel Taxol ® 47 noninterest expense totaled 47 Balance Sheet Assets 47 Nabi HB 47 Nasdaq PGNX today 47 JPY#.# [005] 47 R Interferon beta 46 Mn USD 46 Q#'# Q#'# Q#'# 46 -#,# -#,# [007] 46 TOLMAR Holding Inc. 46 KZT #.#bn [002] 46 Mavrix Mutual Funds 46 Loans Receivable 46 = Net [038] 46 Adjusted OIBDA excludes 46 Bln Update 46 Locteron exclusively 46 GBP GBP 46 - Revenues [019] 46 MSEK -#.# 46 Depreciation Amortization 46 = Three Months [002] 46 ViroChem Pharma Inc. 46 -Von Hippel Lindau 46 REBETOL combination therapy 46 - Operating [015] 46 Accrued royalties 46 SEK -#.# -#.# [002] 46 TRISENOX 46 Sees Q# 46 Segment Profit 46 CLP#.# billion [002] 46 NIS #.#b [002] 46 Margins Improve 46 Rs#.#cr [003] 46 approximately RMB8 46 Interest Expense Net 46 TRACON Pharmaceuticals 46 CAD#.# [001] 46 JPY#.# billion [001] 46 #,# #,# #,# [010] 46 NanoKnife IRE System 46 up#.# [002] 46 infliximab monotherapy 46 kronor euro# 46 Exclude Restructuring 46 #.#ma [005] 46 COST OF GOODS SOLD 46 Lexiscan ® 46 kronor euro#.# [001] 46 BioNeurology 46 SmartGrowth Deposits 46 CZK#.# billion [004] 46 Orthovisc R 46 RECONCILIATION OF OPERATING EARNINGS 46 Newsstand Distribution Services 46 research anddevelopment 46 netincome 46 WESTWOOD ONE INC. SUPPLEMENTAL 46 carboplatin chemotherapy 46 and#.# [001] 46 Change - [011] 46 - - [087] 46 - - Net [052] 46 Q#/# EUR [001] 46 Detrex Corporation Reports 46 IMiDs ® compound 46 - Revenues [022] 46 Reported Adj 46 PHP#.# [007] 46 ISK #.#bn EUR 46 TRY#.# billion 46 Inc. Nasdaq HSNI 46 Shire BioChem Inc. 46 - Revenues [020] 46 Beats Estimate 46 Atria Genetics 46 PMPS brand 46 ELESTAT ® epinastine HCl 46 cash outflow inflow 46 Minimum rents 46 #,#.# #,#.# [008] 46 Noninterest Expense Noninterest expense 46 = Income [004] 46 #,#,# = [009] 46 RUR#.#bn [002] 46 - OperaStankowski 46 OSV segment 46 Taxes Taxes 46 EUR #.#mn [003] 46 - Net [004] 46 - Adjusted EBITDA [001] 46 #.#bn rub [005] 46 - Operating [027] 46 USD#.#m USD#.# per [002] 46 Fazenda Brasileiro Mine 46 INVESTMENT TRUST Consolidated Statements 46 KRW#.# trillion [002] 46 Excluding nonrecurring items 46 nonperforming loans totaled 46 Crofelemer budesonide foam 46 midstage clinical 46 Intangibles amortization 46 SFr#.# billion [002] 46 Discontinued Operations Income Loss 46 epinastine HCl ophthalmic 46 Kasco segment 46 ended December# 46 Below Expectations 46 DAY AVG 46 JPY5 46 phytosterol revenues 46 Background Screening segment 46 c Excludes 46 thethird quarter 46 CHF#.#bn [001] 46 ¥ #.#bn [002] 46 ACQUISITIONS AND 46 - Expenses [016] 46 E#.#m [002] 46 Goods Sold Cost 46 Regulated Businesses 46 Ribavirin royalties 46 QUARTERLY FINANCIAL 46 TEB adjustment 46 pct +#.# [002] 45 EPS Rises 45 #,# -ANDREW J. FERRARO 45 citydwellers rose 45 Normalised earnings 45 USD#.#m USD#.# [002] 45 - - [100] 45 Loan Charge offs 45 Reimbursable revenues 45 - Revenues [008] 45 Endoscopic Technologies 45 AND INCOME TAXES 45 NASDAQ ALNY 45 Consolidated EBITDA Margin 45 hoFH 45 - Non GHanno Coetzee 45 #.#bln [006] 45 #,#.# #,#.# #,#.# [004] 45 DILUTED INCOME 45 Cents Cents Basic 45 ments ments 45 Normalized EBIT 45 refractory chronic lymphocytic 45 - Expenses [004] 45 totaled EUR#.#bn 45 - - Net [047] 45 Segment PTOI 45 RUB#.# [004] 45 Reviewed Reviewed Audited 45 excluding depreciation depletion 45 expenses# [002] 45 Incr 45 Noninterest expense totaled 45 - - [067] 45 adjusted ebitda 45 Mylan Bertek 45 ImperiaLakes Men Association 45 anincrease 45 Core noninterest expense 45 Unaudited Condensed Consolidated 45 QE1 FY 45 Tecstar Automotive Group 45 most heinous hoaxesBy 45 JPY7 45 FORADIL 45 Kogenate ® 45 millionfrom 45 depreciation amortization impairment 45 FFO payout ratio 45 iii Ps 45 Solazed 45 Pharma Merck Serono 45 revenues excluding nonrecurring 45 CIP TRAMADOL ER 45 #-#/# EUR 45 Rs#.#cr [001] 45 CASH FLOW STATEMENTS 45 ARS#.# [007] 45 - - Total [072] 45 bln.togrogs 45 SEK#.# [004] 45 - unaudited unaudbellwether Tele Norte 45 therapeutically inactive prodrug 45 -Itano 45 Nonperforming assets totaled 45 CRIC shareholders 45 - - Net [055] 45 #,#.# [016] 45 Gain Update4 45 interferon alpha Severe 45 Months Ending 45 Wholesale Leathercraft posted 45 GROUP RESULTS 45 RUB #.# [003] 45 PTOI 45 Increlex TM 45 Pharmacia Monsanto 45 Gain Update3 45 - - Net [031] 45 ularitide 45 Inc. NASDAQ TRMS 45 Restructuring Charges 45 income# [001] 45 Equity Compensation Expense 45 Pro forma Adjusted EBITDA 45 -Brookfield Asset Management BAMa.TO 45 Womacks casino 45 +#.# pct [002] 45 quarterof 45 GROSS PROFIT MARGIN 45 Adjusted Diluted EPS 45 Womacks Adjusted EBITDA 45 - - Total [007] 45 Surfactant gross 45 - - [005] 45 - TOTAL [019] 45 = Net [005] 45 CONSOLIDATED PROFIT 45 stereotactic radiosurgery facilities 45 quarterended 45 mn Yen YY 45 MBOED 45 discontinued operations - 45 Tower Homebuilding 45 Belinostat 45 SKK #.# [001] 45 Pro Forma Adjusted EBITDA 45 Equity Investees 45 = Adjusted [008] 45 GBPm GBPm GBPm 45 #.#mn pesos 45 CZK#.# billion [003] 45 Profitability Ratios 45 Seamap equipment 45 Invested assets 45 -Ignacio Galan 45 -Lynnae McCoy 45 Unallocated Corporate 45 noninterest expense partially offset 45 Amortization Expense 45 SmartGrowth Loans 45 RMB#.# billion [001] 45 Profits Slip 45 Previously Securitized Loans 45 #,#,# =Hi Jinx 45 IgG1 monoclonal antibody 45 Q#/# € 45 per MCFE 45 Rs.#.# crores [006] 45 thequarter 45 Pro Forma EBITDA 44 FINANCIAL OVERVIEW 44 Segment EBIT 44 Less Than Estimated 44 LOE decreased 44 - + [011] 44 DIFICID ™ 44 Adjusted pro forma 44 RMB1 #.# 44 Acquisition Related 44 Customer Additions 44 danoprevir 44 Rs #.# [006] 44 EPS prft Y#.# prft 44 StromaCel Inc. 44 + -Thimarafushi 44 #,#,#,# #,#,#,# #,#,#,# 44 * olmesartan medoxomil 44 #,#.# #,#.# - [003] 44 US#.#m [002] 44 Rs.#.# Crores [003] 44 Aldurazyme 44 Salmedix 44 Irma Fioravanti 44 - -UnitedHealthcare Humana 44 trastuzumab Herceptin R 44 SEK -#.# -#.# [001] 44 #-#/# #-#/# [002] 44 -pyar 44 GVIC consolidated 44 = Income [003] 44 nm nm 44 -Ajkai Timfoldgyar plant 44 SEK #.#M #.# 44 - - Net [035] 44 NON OPERATING 44 nondeposit fees 44 RLEC adjusted EBITDA 44 = Reconciliation [006] 44 - - Total [067] 44 INCOME LOSS BEFORE INCOME 44 Supplies Distributors 44 LTM EBITDA ratio 44 - - Net [008] 44 - Operating [012] 44 DATA SNAP Polish 44 Nycomed GmbH 44 docetaxel Taxotere R 44 mucopolysaccharidosis VI MPS VI 44 ninemonths ended 44 #,#,#,# #,#,# 44 Fine Chemicals segment 44 Positively impacting 44 - ASSETS [014] 44 -#.# pct +#.# 44 USD#.#m [006] 44 Vacation Ownership Interest 44 MVAS gross 44 CNY#.# billion [006] 44 #,#.# = LIABILITIES [003] 44 - Operating [018] 44 FIRST NINE MONTHS 44 CHF #'#'# 44 Ended - [025] 44 Loan Charge Offs 44 € #.#ma [003] 44 GROUP BALANCE SHEET 44 Receives Fast Track 44 - SegmentPrincess Dina Mired 44 RUR#.#bn [001] 44 INTANGIBLE ASSETS 44 Cents Cents 44 Disgruntled affiliate 44 Suo Cable 44 More Than Triples 44 Debt #,#.# #,#.# 44 Romaco segment 44 normalized EBIT 44 Noninterest expense decreased 44 leaseable area 44 - -Belusko 44 Proudly Sponsors 44 Rs #.# [001] 44 Company TSX IFP.A 44 million1 44 - Revenues [002] 44 - - Non GAAP [001] 44 Pruvel ™ 44 Engineered Material Systems 44 OPERATING ACTIVITIES 44 Sequential Quarter 44 HRK #.#mn [001] 44 BioTie 44 NASDAQ PGNX